Delayed Puberty in Boys

Definition of Delayed Puberty in a Male Child

• Delayed puberty in a male child is clinically defined as the absence of any secondary sexual characteristics by 14 years of age.
• Specifically, it is defined as the lack of testicular enlargement, characterized by a testicular volume of less than 4 mL or a testicular length of less than 2.5 cm by the age of 14 years.
• Statistically, this definition corresponds to the absence of testicular enlargement at an age that is 2 to 2.5 standard deviations (SD) later than the population mean for the onset of puberty.
• Because adrenarche (the maturation of the adrenal glands resulting in pubic hair, axillary hair, and body odor) can occur independently of gonadarche (the activation of the hypothalamic-pituitary-gonadal axis), the presence of pubic hair alone does not exclude the diagnosis of delayed puberty if testicular enlargement has not occurred.

Etiology of Delayed Puberty

Self-Limited Delayed Puberty (Constitutional Delay of Growth and Puberty)

• Constitutional Delay of Growth and Puberty (CDGP) is the most common cause of delayed puberty in males, accounting for 65% to 80% of cases evaluated in referral centers.
• It represents an extreme variant of normal pubertal timing, characterized by a delayed reactivation of the hypothalamic gonadotropin-releasing hormone (GnRH) pulse generator.
• Children with CDGP typically experience normal growth during the first few years of life, followed by a deceleration in linear growth, with height tracking along the lower percentiles.
• Skeletal maturation (bone age) is characteristically delayed and correlates better with the child's pubertal status than their chronological age.
• CDGP has a strong genetic basis, often inherited in an autosomal dominant pattern (with or without complete penetrance), and a family history of delayed puberty in a parent or sibling is present in 50% to 75% of cases.

Functional Hypogonadotropic Hypogonadism (Transient)

• Functional hypogonadotropic hypogonadism accounts for 10% to 20% of cases and involves a transient suppression of the hypothalamic-pituitary-gonadal axis secondary to an underlying systemic condition.
• Systemic and Chronic Diseases: Conditions such as celiac disease, inflammatory bowel disease (Crohn disease), cystic fibrosis, sickle cell anemia, thalassemia, chronic renal failure, and renal tubular acidosis can delay puberty.
• Nutritional Disorders: Malnutrition, severe weight loss, anorexia nervosa, and excessive physical training (e.g., in wrestlers needing to "make weight") suppress GnRH pulsatility due to inadequate energy stores.
• Endocrine Disorders: Uncontrolled type 1 diabetes mellitus, profound hypothyroidism, Cushing syndrome (or chronic exogenous glucocorticoid therapy), and hyperprolactinemia can impair gonadotropin secretion.

Persistent Hypogonadotropic Hypogonadism (Permanent/Congenital)

• This category, accounting for approximately 10% of cases, results from permanent defects in the hypothalamus or pituitary gland, leading to insufficient secretion of luteinizing hormone (LH) and follicle-stimulating hormone (FSH).
• Isolated Hypogonadotropic Hypogonadism (IHH): Caused by genetic mutations affecting GnRH synthesis, secretion, or receptor function without anatomical brain defects. Implicated genes include GNRHR, GNRH1, KISS1, KISS1R (GPR54), TAC3, and TACR3.
• Kallmann Syndrome: Characterized by hypogonadotropic hypogonadism associated with anosmia or hyposmia. It results from a failure of GnRH-secreting neurons to migrate from the olfactory placode to the hypothalamus. Associated genetic mutations include ANOS1 (KAL1), FGFR1, FGF8, PROK2, PROKR2, and CHD7.
• Combined Pituitary Hormone Deficiencies: Developmental defects of the pituitary gland caused by mutations in transcription factors such as PROP1, POU1F1, LHX3, LHX4, and HESX1 can cause gonadotropin deficiency alongside deficiencies in growth hormone (GH), thyroid-stimulating hormone (TSH), and adrenocorticotropic hormone (ACTH).
• Syndromic Associations: Persistent hypogonadotropic hypogonadism is a feature of genetic syndromes including Prader-Willi syndrome, Bardet-Biedl syndrome, Laurence-Moon syndrome, and CHARGE syndrome.
• Acquired CNS Lesions: Space-occupying lesions (craniopharyngiomas, germinomas, gliomas, astrocytomas, prolactinomas), infiltrative diseases (Langerhans cell histiocytosis, sarcoidosis, hemochromatosis), CNS trauma, cranial irradiation, or neurosurgery can permanently damage the hypothalamic-pituitary axis.

Hypergonadotropic Hypogonadism (Primary Testicular Failure)

• Primary gonadal insufficiency accounts for 5% to 10% of cases. The failure of the testes to produce testosterone and inhibin B leads to a lack of negative feedback, resulting in elevated serum LH and FSH levels.
• Chromosomal Abnormalities: Klinefelter syndrome (47,XXY) is the most common cause. Males typically present with small, firm testes (rarely exceeding 5 mL), tall stature with eunuchoid proportions, and gynecomastia. Degeneration of seminiferous tubules leads to progressive testicular failure and elevated gonadotropins during adolescence.
• Congenital Malformations: Congenital anorchia (vanishing testis syndrome) occurs when functional testicular tissue is lost in utero after initial sex differentiation. Cryptorchidism (undescended testes) can also be associated with primary testicular failure.
• Genetic Syndromes: Noonan syndrome and other RASopathies can present with cryptorchidism and primary testicular failure.
• Defects in Androgen Biosynthesis: Rare autosomal recessive disorders such as congenital lipoid adrenal hyperplasia (StAR mutation), 17-alpha-hydroxylase/17,20-lyase deficiency (CYP17A1), and 17-beta-hydroxysteroid dehydrogenase type 3 deficiency (HSD17B3) impair testosterone synthesis.
• Acquired Testicular Damage: Bilateral testicular torsion, trauma, viral orchitis (e.g., mumps, Coxsackie), autoimmune orchitis, chemotherapy (especially alkylating agents), and direct testicular irradiation can cause irreversible germ cell and Leydig cell destruction.

Diagnostic Approach to a 14-Year-Old Boy with Infantile Genitalia

1. Comprehensive Medical and Family History

• Growth and Development Trajectory: Review previous height and weight records to identify patterns. A slow decline in linear growth velocity during early childhood followed by tracking along a lower percentile strongly suggests Constitutional Delay of Growth and Puberty (CDGP). A complete cessation of growth may indicate acquired hypopituitarism or an eating disorder.
• Family History: A detailed family history is crucial. Inquire about the age of pubertal onset in parents (e.g., age of menarche in the mother, continuation of growth into late teens or late onset of shaving in the father). A history of delayed puberty in parents or siblings strongly points towards CDGP. Elicit any family history of infertility, anosmia, or consanguinity.
• Review of Systems for Chronic Illness: Screen for symptoms of occult systemic diseases that cause functional hypogonadism, such as chronic diarrhea, abdominal pain, or blood in stool (inflammatory bowel disease, celiac disease); polyuria or polydipsia (diabetes or renal disease); or recurrent respiratory infections (cystic fibrosis).
• Nutritional and Psychosocial History: Assess caloric intake, weight loss, body image issues, and exercise intensity to rule out anorexia nervosa or athletic-induced functional hypogonadism.
• Neurological and Olfactory Symptoms: Ask directly about the ability to smell (anosmia or hyposmia), which is pathognomonic for Kallmann syndrome, though patients rarely volunteer this information spontaneously. Screen for headaches, visual disturbances, vomiting, or seizures, which raise suspicion for a central nervous system (CNS) tumor like a craniopharyngioma.
• Past Medical and Surgical History: Inquire about a history of cryptorchidism or microphallus at birth (suggesting congenital hypogonadotropic hypogonadism or partial androgen insensitivity), previous head trauma, CNS infections, or exposure to chemotherapy or radiation.

2. Detailed Physical Examination

• Auxology and Body Proportions: Accurately measure standing height, weight, and calculate the body mass index (BMI). Overweight boys with delayed puberty often have height predictions consistent with their genetic potential, whereas underweight boys are at higher risk for underlying functional or organic pathology.
• Calculate the upper-to-lower segment ratio and measure arm span. An arm span exceeding standing height by more than 5 cm, or an abnormally low upper-to-lower segment ratio, indicates eunuchoid proportions resulting from delayed epiphyseal fusion caused by hypogonadism.
• Genital Examination and Tanner Staging: Use a Prader orchidometer to precisely measure testicular volume. A testicular volume of less than 4 mL (or length < 2.5 cm) confirms prepubertal status (Tanner stage 1).
• Palpate the scrotum to ensure both testes are fully descended and assess their consistency. Small, very firm testes are characteristic of Klinefelter syndrome. Bilateral non-palpable testes may indicate congenital anorchia or severe cryptorchidism.
• Assess stretched penile length and check for structural anomalies such as a bifid scrotum or hypospadias, which may indicate a disorder of sex development (DSD) or severe prenatal androgen deficiency.
• Score pubic hair development separately from genital development, as the presence of pubic hair reflects adrenarche and does not confirm the activation of the gonadal axis.
• Systemic and Dysmorphic Evaluation: Inspect for midline facial defects, cleft lip/palate, or single central maxillary incisor, which are associated with congenital hypopituitarism.
• Look for dysmorphic features characteristic of specific syndromes, such as a webbed neck, ptosis, and short stature (Noonan syndrome), or obesity, hypotonia, and small hands/feet (Prader-Willi syndrome).
• Examine the breast area for gynecomastia, which can be seen in Klinefelter syndrome or certain sex-steroid producing tumors.
• Perform a focused neurological examination, including testing visual fields by confrontation to screen for optic chiasm compression from a pituitary lesion, and formally testing the sense of smell using tools like the University of Pennsylvania Smell Identification Test (UPSIT).
• Examine the skin for hyperpigmentation (suggesting primary adrenal insufficiency or ACTH excess) or signs of chronic nutritional deficiency.

3. First-Line Laboratory and Radiologic Investigations

• Bone Age Radiograph: An anteroposterior X-ray of the left hand and wrist (evaluated using the Greulich and Pyle Atlas) is essential. A delayed bone age (often >2 years behind chronological age) is characteristic of CDGP, allowing the child more time for future growth. It is also used to predict final adult height, though it may overestimate height in CDGP if the delay is severe.
• Basal Gonadotropins (LH and FSH): Obtain early morning serum LH and FSH levels using highly sensitive immunochemiluminometric (ICMA) or immunofluorometric (IFMA) assays (detection limit <0.1 IU/L).
• Elevated LH and FSH levels definitively diagnose primary (hypergonadotropic) hypogonadism, directing the evaluation toward karyotyping and gonadal assessment.
• Low or prepubertal LH and FSH levels indicate either CDGP or hypogonadotropic hypogonadism, which require further dynamic testing to differentiate.
• Serum Testosterone: An early morning serum testosterone level should be measured. A level above 20 ng/dL (0.7 nmol/L) often heralds the clinical onset of puberty within the next 12 to 15 months, supporting a diagnosis of CDGP.
• Screening for Chronic and Systemic Disease: Perform targeted laboratory testing based on history and physical findings. This typically includes a complete blood count (CBC), erythrocyte sedimentation rate (ESR), comprehensive metabolic panel (electrolytes, renal, and liver function), and tissue transglutaminase antibodies (for celiac disease).
• Thyroid and Prolactin Evaluation: Measure free thyroxine (FT4) and TSH to rule out primary or central hypothyroidism. Measure serum prolactin to exclude a prolactinoma, which suppresses GnRH secretion.
• Insulin-Like Growth Factor 1 (IGF-1): Measure IGF-1 to screen for GH deficiency. Results must be interpreted cautiously, as IGF-1 levels are naturally low in prepubertal patients and should be compared against bone age and Tanner stage-matched norms rather than chronological age.

4. Second-Line and Dynamic Endocrine Testing

• Differentiation of CDGP from Hypogonadotropic Hypogonadism (HH): No single test provides 100% accuracy in distinguishing CDGP from isolated HH, and longitudinal clinical follow-up is often the ultimate determinant.
• GnRH or GnRH Agonist Stimulation Test: Administering synthetic GnRH or a GnRH agonist (e.g., leuprolide) and measuring the LH response. A peak LH level >5 to 8 IU/L (depending on the assay) indicates that the pituitary has been primed by endogenous GnRH, suggesting the imminent onset of central puberty (CDGP). A prepubertal or flat response is seen in severe HH, but can also occur in profound CDGP.
• Human Chorionic Gonadotropin (hCG) Stimulation Test: Administered via intramuscular or subcutaneous injections over several days to evaluate Leydig cell functional reserve. A robust rise in testosterone differentiates functional testicular tissue from congenital anorchia and may yield a higher peak testosterone in CDGP compared to permanent HH.
• Serum Inhibin B and Anti-Mullerian Hormone (AMH): These Sertoli cell markers can be measured at any time of day. An inhibin B concentration >35 pg/mL in a prepubertal boy, or >65 pg/mL in a boy with Tanner 2 genitalia, strongly favors a diagnosis of CDGP over congenital hypogonadotropic hypogonadism. Unmeasurable levels confirm primary testicular failure or anorchia.
• Growth Hormone Provocation Testing: If linear growth velocity is severely impaired and IGF-1 is low, provocative GH testing (e.g., using clonidine, arginine, or glucagon) may be indicated. Because low sex steroids naturally blunt GH secretion, the patient must be primed with exogenous testosterone prior to the test to prevent a false-positive diagnosis of GH deficiency.

5. Advanced Imaging and Genetic Evaluation

• Magnetic Resonance Imaging (MRI) of the Brain and Pituitary: Indicated immediately if there are neurological signs, visual field defects, anosmia, extreme short stature, or severe headaches. In the absence of focal signs, MRI is typically deferred until 15 years of age if spontaneous puberty has not commenced. The MRI should specifically evaluate the hypothalamic-pituitary region and assess the olfactory bulbs and sulci (aplasia or hypoplasia confirms Kallmann syndrome).
• Karyotype Analysis: A peripheral blood karyotype is mandatory if basal gonadotropins (LH/FSH) are elevated, to definitively diagnose Klinefelter syndrome (47,XXY) or other chromosomal anomalies causing gonadal dysgenesis.
• Targeted Genetic Testing: If isolated hypogonadotropic hypogonadism is suspected (especially if associated with anosmia, midline defects, or a strong family history), genetic sequencing panels covering mutations such as KAL1, FGFR1, GNRHR, and KISS1R should be considered.